AstraZeneca weighs linking CEO closer to sales target

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (NYSE:AZN) is looking at ways to link pay for Chief Executive Pascal Soriot and other top managers more directly to the drugmaker's target of achieving revenue of $45B by 2023.

Soriot successfully fought off a $118B takeover attempt by Pfizer in 2014, in part by promising a more than 70% jump in sales within a decade.

But many analysts remain uncertain about that target and the U.K. firm's shares are languishing well below Pfizer's offer price.

Subscribe for full text news in your inbox